An open-label trial of acamprosate in the treatment of pathological gambling

Participants with DSM-IV criteria for PG received acamprosate in an 8-week, open-label trial following a 2-week observation. The pri-mary efficacy measure was the Yale-Brown Obsessive Compulsive Scale modified for PG (Y-BOCS-PG). Secondary efficacy measures included the Gambling Severity Assessment Scale (GSAS), the Clinical Global Impression (CGI) Improvement and Severity Scales, a patient self-rated global rating, the Hamilton Depression Rating Scale (HDRS), the Sheehan Disability Scale (SDS), and the Timeline Follow Back. The study was con-ducted at 2 sites.